Viewray Inc (VRAY) CEO Scott William Drake Purchases 60,000 Shares
Viewray Inc (NASDAQ:VRAY) CEO Scott William Drake acquired 60,000 shares of the stock in a transaction dated Tuesday, November 13th. The shares were purchased at an average price of $6.47 per share, for a total transaction of $388,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of VRAY traded up $0.17 on Tuesday, reaching $6.28. 2,565,600 shares of the stock traded hands, compared to its average volume of 1,110,517. The stock has a market cap of $498.62 million, a PE ratio of -6.38 and a beta of 1.17. The company has a current ratio of 3.33, a quick ratio of 2.64 and a debt-to-equity ratio of 1.17. Viewray Inc has a 12 month low of $5.80 and a 12 month high of $13.21.
Viewray (NASDAQ:VRAY) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). Viewray had a negative net margin of 105.09% and a negative return on equity of 223.23%. The company had revenue of $17.70 million during the quarter, compared to the consensus estimate of $17.77 million. During the same quarter last year, the company earned ($0.19) earnings per share. The business’s revenue was up 45.1% on a year-over-year basis. Equities analysts forecast that Viewray Inc will post -0.8 earnings per share for the current fiscal year.
VRAY has been the topic of a number of research reports. BidaskClub upgraded Viewray from a “hold” rating to a “buy” rating in a research report on Friday, July 20th. ValuEngine cut Viewray from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 8th. BTIG Research restated a “buy” rating and set a $14.00 price objective on shares of Viewray in a research report on Tuesday, August 7th. Mizuho restated a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Monday, August 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Wednesday, October 3rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Viewray presently has a consensus rating of “Buy” and a consensus target price of $12.79.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Recommended Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.